Journals / Retina-Vitreus / 2020 / Cilt: 29 - Sayı: 3

Assessment of Effective Dose Preparability of Bevacizumab for Intraocular Administration

Pages
281–284
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The drug should be available in a disposable syringe suitable for intravitreal use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the effective dosing of Bevacizumab in the operating room conditions divided by the form suitable for parenteral use and identify individual differences in its preparation.
📊
Key Findings & Data:Materials and Methods: Intravitreal Bevacizumab was prepared in 3 different groups from 100 mg / 4 ml Bevacizumab (Altuzan-Roche / USA) vial produced for parenteral use under laboratory conditions.
💡
Conclusion & Impact:The drug should be available in a disposable syringe suitable for intravitreal use.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the effective dosing of Bevacizumab in the operating room conditions divided by the form suitable for parenteral use and identify individual differences in its preparation. Materials and Methods: Intravitreal Bevacizumab was prepared in 3 different groups from 100 mg / 4 ml Bevacizumab (Altuzan-Roche / USA) vial produced for parenteral use under laboratory conditions. The fi rst two groups were formed by two blinded ophthalmologists, who had previously had experience in preparing intravitreal injections, by asking them to prepare 12 intravitreal Bevacizumab doses (1.25 mg / 50 μl) of insulin injectors. Group 3 was prepared by taking a fi xed dose of 50 μl volume using a Hamilton injector. Samples were evaluated by spectrophotometric analysis. The calibration graph was drawn and the results obtained in the study were determined within the 95% confi dence interval. Results: Samples were evaluated in three groups. The mean amount of Bevacizumab prepared in Group 1 was 84.964 ± 6.03 μl, while it was 58.48 ± 5.65 μl in Group 2. The difference was statistically signifi cant between the two groups. There was also a statistically signifi cant difference between the two groups with the samples prepared using a Hamilton injector. Conclusion: The use of intravitreal bevacizumab is discussed with the latest decision for intravitreal injections, especially because of the increased risk of endophthalmitis. In addition, it is not possible to prepare a fi xed amount of medicine for each patient due to handmade division. The drug should be available in a disposable syringe suitable for intravitreal use.

🔖

Cite This Article

KARACA, U., USTA, G. (2022). Assessment of Effective Dose Preparability of Bevacizumab for Intraocular Administration. Retina-Vitreus, Cilt: 29 - Sayı: 3, 281–284. https://ajindex.com/articles/589083

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26(9):999-1005
  2. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profi le and management of adverse events. Semin Oncol 2006;33(5 Suppl 10):S26-34
  3. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113(3):363-372.e5
  4. Sacha G, Rogers JA, Miller RL. Pre-fi lled syringes: a review of the history, manufacturing and challenges. Pharm Dev Technol 2015;20(1):1-11
  5. Küçükevcilioğlu M, Durukan AH, Güngör R, Erdurman FC, Mumcuoğlu T, Hürmeriç V, Sobacı G, Bayraktar MZ. Göz içi enjeksiyonların epidemiyolojisi. Gülhane Tıp Dergisi 2011;53(4):233-236
  6. Yannuzzi NA, Klufas MA, Quach L, Beatty LM, Kaminsky SM, Crystal RG, D'Amico DJ, Kiss S. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol 2015;133(1):32-9
  7. Palmer JM, Amoaku WM, Kamali F. Quality of bevacizumab compounded for intravitreal administration. Eye (Lond) 2013;27(9):1090-7
  8. Kahook MY, Liu L, Ruzycki P, Mandava N, Carpenter JF, Petrash JM, Ammar DA. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30(6):887-92
  9. Moisseiev E, Rudell J, Tieu EV, Yiu G. Effect of Syringe Design on the Accuracy and Precision of Intravitreal Injections of Anti-VEGF Agents. Curr Eye Res 2017;42(7):1059-1063
  10. Loewenstein I, Goldstein M, Moisseiev J, Moisseiev E. Accuracy and precision of intravitreal injections of antivascular endothelial growth factor agents in real life: What Is Actually in the Syringe? Retina 2019;39(7):1385-1391
  11. Cole KD, DeRose P, He HJ, Stein EV, Lang B, Schiel J, Urbas A, Solis E, Choquette S. NIST Spectroscopic Measurement Standards. Biopharm Int 2018;31(4):22-34.